RedHill Biopharma reported $50.92B in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Cara Therapeutics USD 9.38M 9.38M Sep/2025
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1.02M Dec/2025
Cronos Group USD 376.26M 5.33M Mar/2026
RedHill Biopharma USD 50.92B 17.62B Dec/2025